Abliva
Abliva AB is a Swedish pharmaceutical company focused on the research and development of treatments for primary mitochondrial diseases, which are rare and severe conditions caused by dysfunctional mitochondria. The company's pipeline includes KL1333, currently in phase I clinical trials, and NV354, an energy replacement therapy that is preparing for clinical trials. KL1333 is noted for its role as a regulator of NAD+ and NADH, and has received orphan drug designation in both Europe and the United States. Additionally, Abliva is developing NeuroSTAT for the treatment of traumatic brain injury. Established in 2000 and headquartered in Lund, Sweden, Abliva has formed collaborations with various institutions, enhancing its research capabilities and clinical development efforts.
Isomerase
Funding Round in 2016
Isomerase is a biotechnology company that specializes in leveraging microbial technologies to develop a wide array of products, including therapeutics, enzymes, agricultural goods, and consumer products. By utilizing its extensive expertise in working with bacteria and fungi, Isomerase offers partners a comprehensive suite of services in microbial product and process discovery and development. The company focuses on synthetic biology, microbial strain development, genome editing, enzyme engineering, and fermentation optimization, enabling efficient and sustainable production processes. Isomerase's innovative approach combines deep knowledge in biology and chemistry with advanced process development techniques, helping partners accelerate their product commercialization efforts while maintaining cost-effectiveness and scalability.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.